New Facility to Service Growing Business in Textiles, Global Supply Chains from the Asia Pacific Region
STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ:APDN, “Applied DNA,” “the Company”) today announced the establishment of a Central DNA Testing Laboratory in Ahmedabad, India providing full forensic authentication services. The laboratory supports Applied DNA’s growing global textile business in the Asia-Pacific region with expansion capability for other supply chains present in the region, such as fertilizer and pharmaceuticals. Officially opening on February 15, 2018, the Central Laboratory is strategically located in the state of Gujarat, an economic hub for the development and advancement of cotton, other textiles, fertilizers, petrochemicals and pharmaceuticals.
Dr. Ila Lansky, a forensic scientist with over 11 years of forensic DNA experience, will direct the Central DNA Testing Laboratory. She currently oversees all aspects of forensic analysis, testing, authentication and reporting for all samples submitted, following the standard operating procedures established by Applied DNA’s New York forensic laboratories. The Central DNA Testing Laboratory is a high throughput laboratory, providing customers with accurate reports in a short turnaround time.
“This is an important opportunity for Applied DNA to bring our proven technologies to the heart of India’s textile industry, and share our impeccable standards and operational protocols,” said Dr. Lansky. “The laboratory will have the ability to process thousands of samples, serving our textiles customers in the region.”
The Indian textile industry is currently estimated at approximately $135 billion USD and is expected to reach $230 billion by 2023 (IBEF 2017). It is home to such global textile brands and manufacturers as The Himatsingka Group and GHCL Limited. Additionally, India is home to the sixth largest pharmaceutical market in the world, with an expected value of $550 billion by 2020 (IBEF 2017).
“Opening a lab in Gujarat has both strategic and practical importance for Applied DNA,” said Dr. James A. Hayward, president and chief executive officer of Applied DNA. “Our partnership with Himatsingka has proven remarkably successful, with uptake in the commercial ecosystem and endorsement by big box retailers. Adoption of our technologies by other textile companies is growing. Working closely with such India-based industry majors as Himatsingka and GHCL, we know Applied DNA’s value in enabling source-verified supplied chains and contributing the steady growth and ensured protection of the circular economy. It only makes sense for Applied DNA to have a facility where so many of our current and future partners are based.”
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics. The Company makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.
The proprietary DNA-based CertainT® platform can be used to identify, tag, test, and track products, to help assure authenticity, origin, traceability, sustainability and quality of products. SigNature® DNA describes the core technology ingredient that is at the heart of a family of uncopyable, security and authentication solutions such as SigNature®T and fiberTyping®, targeted towards textiles and apparel, BackTrac® and DNAnet®, for anti-theft and loss prevention, and digitalDNA®, providing powerful track-and-trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators. Applied DNA Sciences is also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.
The statements made by APDN in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 28, 2017, which is available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.
Applied DNA Sciences
Sanjay M. Hurry, 212-838-3777
Angie Mathews, 781-639-4924
MeiLin Wan, 631-240-8849